The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms

@article{Sindrup1990TheSS,
  title={The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms},
  author={S{\o}ren H Sindrup and Lars Freng Gram and Kim Br{\o}sen and Ole Esh{\o}j and Erik F. Mogensen},
  journal={Pain},
  year={1990},
  volume={42},
  pages={135-144}
}
&NA; The effect of the selective serotonin reuptake inhibitor paroxetine on diabetic neuropathy symptoms was examined in comparison to imipramine and placebo in a randomised, double‐blind, cross‐over study. Paroxetine was given as a fixed dose of 40 mg/day, while the dose of imipramine was adjusted to yield optimal plasma levels of imipramine plus desipramine of 400–600 nM. Paroxetine significantly reduced the symptoms of neuropathy as measured by both observer‐ and self‐rating, but was… Expand
The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy
TLDR
Compared with earlier results obtained with imipramine administered on the basis of plasma level monitoring, citalopram appeared to be less effective, but seemed to be better tolerated. Expand
Lack of effect of mianserin on the symptoms of diabetic neuropathy
TLDR
In contrast to drugs with documented effects on the symptoms of diabetic neuropathy, mianserin has a very weak or no inhibitory effect on 5-HT and noradrenaline reuptake and this may explain its poor clinical effect. Expand
Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.
TLDR
Paroxetine appears to be a more attractive option than tricyclic antidepressants for the treatment of depression in late life because of its better tolerability profile and potentially lower toxicity in overdosage and in patients with cardiovascular disease. Expand
Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.
TLDR
Desipramine relieves pain caused by diabetic neuropathy with efficacy similar to that of amitriptyline, offering an alternative for patients unable to tolerate the latter and blockade of norepinephrine reuptake is likely to mediate the analgesic effect of these antidepressant drugs in diabetic Neuropathy. Expand
Concentration‐response relationship in imipramine treatment of diabetic neuropathy symptoms
TLDR
The dose‐dependent kinetics of imipramine was confirmed, and dose increments should be carried out in small steps and preferably with monitoring of drug levels, and the effect of treatment was evaluated by use of visual analog scales. Expand
Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial
TLDR
Desipramine relieves pain in many patients with painful diabetic neuropathy, offering an alternative for patients unable to tolerate amitriptyline, and blockade of norepinephrine reuptake may mediate this analgesic effect. Expand
Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity
TLDR
It is suggested that at standard dosages noradrenergic agents may provide more effective analgesia in back pain than do selective serotonergic reuptake inhibitors. Expand
Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study.
TLDR
Compared with earlier results obtained with imipramine dosed on the basis of plasma level monitoring, clomipramines on fixed doses appeared less efficacious whereas the side effect profiles were the same. Expand
Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy
TLDR
Cross‐validation sensitivity analysis of results support the conclusion that nortriptyline provides modest improvement at best over placebo in terms of chemotherapy‐related neuropathy, and Linear models analysis and Bayes methods confirmed that the effect of nortriptYline on paresthesia was modest at best. Expand
Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders.
  • W. Heydorn
  • Medicine
  • Expert opinion on investigational drugs
  • 1999
TLDR
The efficacy seen in short-term studies with paroxetine in the treatment of depression is maintained when the drug is given chronically, and the compound shows efficacy superior to placebo, and similar to that obtained with standard tricyclic or tetracyclic agents. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
A double-blind controlled study of a serotonin uptake inhibitor (Zimelidine) versus placebo in chronic pain patients
TLDR
Patients in the Zimelidine group experienced significantly more pain relief and tended to be able to reduce their need for analgesics more often than the patients in the placebo group. Expand
Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.
TLDR
The results indicate that aldose reductase inhibitor treatment may be of value in diabetic polyneuropathy, and provide support for the sorbitol pathway hypothesis of diabetic polyNEuropathy. Expand
Pain Relief in Diabetic Neuropathy: The Effectiveness of Imipramine and Related Drugs
  • R. Young, B. Clarke
  • Medicine
  • Diabetic medicine : a journal of the British Diabetic Association
  • 1985
TLDR
Experience of treating 80 consecutive patients with painful diabetic neuropathy and a double‐blind study of imipramine in acute painful neuropathy are reported, suggesting a peripheral rather than central drug action. Expand
A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy.
TLDR
There is no justification for the use of these agents in the treatment of painful neuropathy outside of large, controlled clinical trials, according to a reevaluation of previous trials. Expand
Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.
TLDR
The changes in both expiration-inspiration ratios and resting minimal heart rate are consistent with a sorbinil-related improvement in cardiac parasympathetic nerve function, as indicated by unaltered glycohemoglobin levels. Expand
Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.
TLDR
The changes in both expiration-inspiration ratios and resting minimal heart rate are consistent with a sorbinil-related improvement in cardiac parasympathetic nerve function, as indicated by unaltered glycohemoglobin levels. Expand
Imipramine treatment of painful diabetic neuropathy.
TLDR
The rating of specific symptoms at the end of each treatment period showed a beneficial effect of imipramine on pain, paresthesia, dysesthesia, numbness, and nocturnal aggravation. Expand
MEXILETINE FOR TREATMENT OF CHRONIC PAINFUL DIABETIC NEUROPATHY
TLDR
Assessment with a five-item clinical symptom scale showed significant improvement during the mexiletine phase compared with the placebo phase, and pain was reduced during mex toiletine but not during placebo, as assessed by a visual analogue rating scale. Expand
Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study
TLDR
A controlled clinical trial on the efficacy of a nortriptyline-fluphenazine combination was carried out in patients with painful diabetic polyneuropathy and significant relief of both pain and paresthesia was obtained. Expand
Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood
TLDR
It is concluded that amitriptyline relieves pain in diabetic neuropathy; this effect is independent of mood elevation. Expand
...
1
2
3
...